purchase customization

1 Study Coverage
1.1 Biosimilar Insulin Glargine Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilar Insulin Glargine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Market by Application
1.3.1 Global Biosimilar Insulin Glargine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biosimilar Insulin Glargine Sales Estimates and Forecasts 2017-2028
2.2 Global Biosimilar Insulin Glargine Revenue Estimates and Forecasts 2017-2028
2.3 Global Biosimilar Insulin Glargine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Biosimilar Insulin Glargine Sales by Region
2.4.1 Global Biosimilar Insulin Glargine Sales by Region (2017-2022)
2.4.2 Global Sales Biosimilar Insulin Glargine by Region (2023-2028)
2.5 Global Biosimilar Insulin Glargine Revenue by Region
2.5.1 Global Biosimilar Insulin Glargine Revenue by Region (2017-2022)
2.5.2 Global Biosimilar Insulin Glargine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Biosimilar Insulin Glargine Sales by Manufacturers
3.1.1 Global Top Biosimilar Insulin Glargine Manufacturers by Sales (2017-2022)
3.1.2 Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilar Insulin Glargine in 2021
3.2 Global Biosimilar Insulin Glargine Revenue by Manufacturers
3.2.1 Global Biosimilar Insulin Glargine Revenue by Manufacturers (2017-2022)
3.2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Insulin Glargine Revenue in 2021
3.3 Global Biosimilar Insulin Glargine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Biosimilar Insulin Glargine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biosimilar Insulin Glargine Sales by Type
4.1.1 Global Biosimilar Insulin Glargine Historical Sales by Type (2017-2022)
4.1.2 Global Biosimilar Insulin Glargine Forecasted Sales by Type (2023-2028)
4.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
4.2 Global Biosimilar Insulin Glargine Revenue by Type
4.2.1 Global Biosimilar Insulin Glargine Historical Revenue by Type (2017-2022)
4.2.2 Global Biosimilar Insulin Glargine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
4.3 Global Biosimilar Insulin Glargine Price by Type
4.3.1 Global Biosimilar Insulin Glargine Price by Type (2017-2022)
4.3.2 Global Biosimilar Insulin Glargine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Biosimilar Insulin Glargine Sales by Application
5.1.1 Global Biosimilar Insulin Glargine Historical Sales by Application (2017-2022)
5.1.2 Global Biosimilar Insulin Glargine Forecasted Sales by Application (2023-2028)
5.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
5.2 Global Biosimilar Insulin Glargine Revenue by Application
5.2.1 Global Biosimilar Insulin Glargine Historical Revenue by Application (2017-2022)
5.2.2 Global Biosimilar Insulin Glargine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
5.3 Global Biosimilar Insulin Glargine Price by Application
5.3.1 Global Biosimilar Insulin Glargine Price by Application (2017-2022)
5.3.2 Global Biosimilar Insulin Glargine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biosimilar Insulin Glargine Market Size by Type
6.1.1 North America Biosimilar Insulin Glargine Sales by Type (2017-2028)
6.1.2 North America Biosimilar Insulin Glargine Revenue by Type (2017-2028)
6.2 North America Biosimilar Insulin Glargine Market Size by Application
6.2.1 North America Biosimilar Insulin Glargine Sales by Application (2017-2028)
6.2.2 North America Biosimilar Insulin Glargine Revenue by Application (2017-2028)
6.3 North America Biosimilar Insulin Glargine Market Size by Country
6.3.1 North America Biosimilar Insulin Glargine Sales by Country (2017-2028)
6.3.2 North America Biosimilar Insulin Glargine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Biosimilar Insulin Glargine Market Size by Type
7.1.1 Europe Biosimilar Insulin Glargine Sales by Type (2017-2028)
7.1.2 Europe Biosimilar Insulin Glargine Revenue by Type (2017-2028)
7.2 Europe Biosimilar Insulin Glargine Market Size by Application
7.2.1 Europe Biosimilar Insulin Glargine Sales by Application (2017-2028)
7.2.2 Europe Biosimilar Insulin Glargine Revenue by Application (2017-2028)
7.3 Europe Biosimilar Insulin Glargine Market Size by Country
7.3.1 Europe Biosimilar Insulin Glargine Sales by Country (2017-2028)
7.3.2 Europe Biosimilar Insulin Glargine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biosimilar Insulin Glargine Market Size by Type
8.1.1 Asia Pacific Biosimilar Insulin Glargine Sales by Type (2017-2028)
8.1.2 Asia Pacific Biosimilar Insulin Glargine Revenue by Type (2017-2028)
8.2 Asia Pacific Biosimilar Insulin Glargine Market Size by Application
8.2.1 Asia Pacific Biosimilar Insulin Glargine Sales by Application (2017-2028)
8.2.2 Asia Pacific Biosimilar Insulin Glargine Revenue by Application (2017-2028)
8.3 Asia Pacific Biosimilar Insulin Glargine Market Size by Region
8.3.1 Asia Pacific Biosimilar Insulin Glargine Sales by Region (2017-2028)
8.3.2 Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Biosimilar Insulin Glargine Market Size by Type
9.1.1 Latin America Biosimilar Insulin Glargine Sales by Type (2017-2028)
9.1.2 Latin America Biosimilar Insulin Glargine Revenue by Type (2017-2028)
9.2 Latin America Biosimilar Insulin Glargine Market Size by Application
9.2.1 Latin America Biosimilar Insulin Glargine Sales by Application (2017-2028)
9.2.2 Latin America Biosimilar Insulin Glargine Revenue by Application (2017-2028)
9.3 Latin America Biosimilar Insulin Glargine Market Size by Country
9.3.1 Latin America Biosimilar Insulin Glargine Sales by Country (2017-2028)
9.3.2 Latin America Biosimilar Insulin Glargine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Biosimilar Insulin Glargine Market Size by Type
10.1.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Biosimilar Insulin Glargine Revenue by Type (2017-2028)
10.2 Middle East and Africa Biosimilar Insulin Glargine Market Size by Application
10.2.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Biosimilar Insulin Glargine Revenue by Application (2017-2028)
10.3 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country
10.3.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Eli Lilly Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eli Lilly Recent Developments
11.2 Gan&Lee
11.2.1 Gan&Lee Corporation Information
11.2.2 Gan&Lee Overview
11.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Gan&Lee Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Gan&Lee Recent Developments
11.3 Tonghua Dongbao
11.3.1 Tonghua Dongbao Corporation Information
11.3.2 Tonghua Dongbao Overview
11.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Tonghua Dongbao Recent Developments
11.4 United Laboratory
11.4.1 United Laboratory Corporation Information
11.4.2 United Laboratory Overview
11.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 United Laboratory Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 United Laboratory Recent Developments
11.5 Geropharm
11.5.1 Geropharm Corporation Information
11.5.2 Geropharm Overview
11.5.3 Geropharm Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Geropharm Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Geropharm Recent Developments
11.6 Biocon
11.6.1 Biocon Corporation Information
11.6.2 Biocon Overview
11.6.3 Biocon Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Biocon Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Biocon Recent Developments
11.7 Wockhardt
11.7.1 Wockhardt Corporation Information
11.7.2 Wockhardt Overview
11.7.3 Wockhardt Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Wockhardt Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Wockhardt Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biosimilar Insulin Glargine Industry Chain Analysis
12.2 Biosimilar Insulin Glargine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilar Insulin Glargine Production Mode & Process
12.4 Biosimilar Insulin Glargine Sales and Marketing
12.4.1 Biosimilar Insulin Glargine Sales Channels
12.4.2 Biosimilar Insulin Glargine Distributors
12.5 Biosimilar Insulin Glargine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Biosimilar Insulin Glargine Industry Trends
13.2 Biosimilar Insulin Glargine Market Drivers
13.3 Biosimilar Insulin Glargine Market Challenges
13.4 Biosimilar Insulin Glargine Market Restraints
14 Key Findings in The Global Biosimilar Insulin Glargine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer